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Reliable evaluation of the potential hazard to
children from ingestion of lead in the environ-
ment depends in part on accurate information
on the rate and extent of Pb absorption
(“bioavailability”) from each exposure medium.
This is especially true for soil because Pb in soil
can exist in a variety of different mineral forms
and particle types, some of which tend to have
low absorbability. Thus, equal ingested doses
of different forms of Pb in soil may not be of
equal health concern.
Oral bioavailability of Pb in a particular
medium may be expressed either in absolute
terms [absolute bioavailability (ABA)] or in
relative terms [relative bioavailability (RBA)].
ABA is the fraction of Pb that reaches the
systemic circulation after oral ingestion.
Typically, ABA is measured by comparing
the time course of absorption after both oral
and intravenous (iv) doses and comparing
the area under the curve (AUC) of blood Pb
concentration versus time:
[1]
This ratio is also referred to as the oral absorp-
tion fraction. RBA is the ratio of the ABA of
Pb present in some test material compared
with the ABA of Pb in some appropriate refer-
ence material:
[2]
Usually, the form of Pb used as a reference
material is a soluble compound, such as Pb
acetate, that is expected to completely dis-
solve in gastrointestinal ﬂuids when ingested.
We have been engaged in a multiyear
investigation of Pb absorption in juvenile
swine after oral exposure to a variety of dif-
ferent environmental media, especially soils
and solid wastes associated with mining,
milling, and smelting sites. Initial studies in
the program (referred to as “Phase 0” and
“Phase I”) were performed by R. Poppenga
and B. Thacker at Michigan State University
(Weis et al. 1995). The study designs and
protocols developed during the early studies
were reﬁned and standardized (by S. Casteel,
at the University of Missouri–Columbia) and
applied to a number of different test materials
collected from various Superfund sites. This
series of measurements is collectively referred
to as “Phase II,” and the results are presented
in this article. A more detailed presentation of
the Phase II work, including raw data from
all studies, is available from the U.S.
Environmental Protection Agency (U.S. EPA
2006). Drexler and Brattin (in press) have
compared the results of the Phase II in vivo
studies with the results of an in vitro tech-
nique for estimating Pb RBA in soil samples.
Materials and Methods
Animals. Juvenile swine were selected for use
in this program because they are considered a
good model for the gastrointestinal system of
a human child (U.S. EPA 2006; Weis et al.
1995). All animals were intact males of the
Pig Improvement Corporation genetically
defined Line 26, purchased from Chinn
Farms (Clarence, MO). Animals were usually
purchased at 4–5 weeks of age (weaning
occurs at 3 weeks of age). In general, about
10% more pigs were purchased than were
required for the experimental design. All ani-
mals were held under quarantine for 1 week to
allow us to observe their health and cull any
sick animals from the study. In addition, to
minimize weight variations among animals
and groups, we excluded extra animals that
were most different in body weight (either
heavier or lighter than average) 4 days before
exposure began. The remaining animals were
assigned to dose groups at random (typically
ﬁve animals per group). When exposure began
(day 0), the animals were about 5–6 weeks of
age and weighed an average of approximately
8–11 kg.
All animals were housed in individual
stainless steel cages. Each animal was exam-
ined by a certiﬁed veterinary clinician (swine
specialist) before being placed on study, and
each was examined daily by an attending
veterinarian while on study. Blood samples
were collected by venipuncture for clinical
chemistry and hematologic analysis on
days 4, 7, and 15 to assist in clinical health
assessments. Any animal that became ill and
could not be promptly restored to good
health by appropriate treatment was removed
from the study. All animals were treated
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In this article we summarize the results of a series of studies that measured the relative bioavail-
ability (RBA) of lead in a variety of soil and soil-like test materials. Reference material (Pb acetate)
or Pb-contaminated soils were administered orally to juvenile swine twice a day for 15 days. Blood
samples were collected from each animal at multiple times during the course of the study, and
samples of liver, kidney, and bone were collected at sacriﬁce. All samples were analyzed for Pb. We
estimated the RBA of a test material by ﬁtting mathematical models to the dose–response curves
for each measurement end point and ﬁnding the ratio of doses that gave equal responses. The ﬁnal
RBA for a test material is the simple average of the four end point–speciﬁc RBA values. Results
from 19 different test materials reveal a wide range of RBA values across different exposure mate-
rials, ranging from 6 to 105%. This variability in RBA between different samples highlights the
importance of reliable RBA data to help improve risk assessments for Pb in soil. Although the
RBA value for a sample depends on the relative amounts of the different chemical and physical
forms of Pb present, data are not yet adequate to allow reliable quantitative predictions of RBA
from chemical speciation data alone. Key words: lead, RBA, relative bioavailability, swine. Environ
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[Online 4 April 2006]humanely and with regard for alleviation of
suffering.
Diet. Animals provided by the supplier
were weaned onto standard pig chow pur-
chased from MFA Inc. (Columbia, MO). To
minimize Pb exposure from the diet, the ani-
mals were gradually transitioned from the
MFA feed to a special low-Pb feed (guaran-
teed < 0.2 mg/kg Pb; Zeigler Brothers Inc.,
Gardners, PA) from day –7 (7 days before
exposure began) to day –3; this low-Pb feed
was then provided for the duration of the
study. The feed was nutritionally complete
and met all requirements of the National
Institutes of Health–National Research
Council (NRC) for swine rations (NRC
1988). Periodic analysis of feed samples dur-
ing this program indicated the mean Pb level
was below the detection limit (0.05 mg/kg),
corresponding to a daily intake of < 2.5
μg/kg/day.
Each day every animal was given an
amount of feed equal to 5% of the mean body
weight of all animals on study. Feed was
administered in two equal portions of 2.5% of
the mean body weight at each feeding. Feed
was provided at 1100 hr and 1700 hr daily.
Drinking water was provided ad libitum via
self-activated watering nozzles within each
cage. Periodic analysis of samples from ran-
domly selected drinking water nozzles indi-
cated the mean Pb concentration in water was
< 2 μg/L, corresponding to a daily intake of
< 0.2 μg/kg/day.
Test materials. Table 1 describes the
Phase II test materials for which RBA was
measured and provides the analytical results
for Pb. We investigated 17 different samples
from eight different sites, along with one sam-
ple of paint ﬂakes mixed with clean soil and
one sample of finely ground native galena
mixed with clean soil. Before analysis and
dosing, all samples were dried (< 40°C) and
sieved; only materials that passed through a
60-mesh screen (corresponding to particles
smaller than approximately 250 μm) were
used, with the exception of the two samples
from study 5 (test materials 7 and 8), which
were sieved to 150 μm. We selected this range
of particle sizes because the U.S. EPA consid-
ers particles < 250 μm to be the most likely to
adhere to hands and be ingested by children
(U.S. EPA 2000b).
Each sample of test material that was eval-
uated in the swine bioassay program was thor-
oughly characterized with regard to mineral
phase, particle size distribution, and matrix
association using electron microprobe analysis.
The relative Pb mass (RLM) in each phase is
the length-weighted fraction of the total Pb in
a sample that is present in a particular phase i,
calculated by summing across all particles in
phase i as follows:
Relative bioavailability of lead
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Table 1. Description of Phase II test materials.
Test  Pb concentration
material Study Sample designation Site Sample description (ppm)a
1 2 Bingham Creek Kennecott NPL site,  Soil composite of samples containing < 2,500 ppm Pb; collected  1,590
Residential Salt Lake City, Utah from a residential area (Jordan View Estates) located along 
Bingham Creek in the community of West Jordan, Utah
2 2 Bingham Creek Kennecott NPL site,  Soil composite of samples containing ≥ 3,000 ppm Pb; collected  6,330
Channel Soil Salt Lake City, Utah from a residential area (Jordan View Estates) located along 
Bingham Creek in the community of West Jordan, Utah
3 3 Jasper County Jasper County, Missouri, Soil composite collected from an on-site location 10,800
High Lead Smelter Superfund site
4 3 Jasper County Jasper County, Missouri, Soil composite collected from an on-site location 4,050
Low Lead Yard Superfund site
5 4 Murray Smelter Murray Smelter Superfund site, Composite of samples collected from areas where exposed slag  11,700
Slag Murray City, Utah existed on site
6 4 Jasper County Jasper County, Missouri, Soil composite collected from an on-site location 6,940
High Lead Mill Superfund site
7 5 Aspen Berm Smuggler Mountain NPL site, Composite of samples collected from the racquet club property  14,200
Aspen, Colorado (including a parking lot and a vacant lot)
8 5 Aspen Residential Smuggler Mountain NPL site,  Composite of samples collected from residential properties within  3,870
Aspen, Colorado the study area
9 6 Midvale Slag Midvale Slag NPL site, Composite of samples collected from a water-quenched slag pile in  8,170
Midvale, Utah Midvale Slag Operable Unit 2
10 6 Butte Soil Silver Bow Creek/Butte Area Soil composite collected from waste rock dumps in Butte 8,530
NPL site, Butte, Montana Priority Soils Operable Unit
11 7 California Gulch Phase I California Gulch NPL site, Soil composite collected from residential properties within Leadville 7,510
Residential Soil Leadville, Colorado
12 7 California Gulch California Gulch NPL site, Soil composite collected from near the Lake Fork Trailer Park located 4,320
Fe/Mn PbO Leadville, Colorado southwest of Leadville near the Arkansas River
13 8 California Gulch AV California Gulch NPL site, Sample collected from a water-quenched slag pile on the property of 10,600
Slag Leadville, Colorado the former AV (Arkansas Valley) Smelter, located just west of Leadville
14 9 Palmerton Location 2 New Jersey Zinc NPL site, Soil composite collected on-site 3,230
Palmerton, Pennsylvania
15 9 Palmerton Location 4 New Jersey Zinc NPL site, Soil composite collected on-site 2,150
Palmerton, Pennsylvania
16 11 Murray Smelter Murray Smelter Superfund site, Soil composite collected on-site 3,200
Soil Murray City, Utah
17 11 NIST Paint NA A mixture of approximately 5.8% NIST SRM 2589band 94.2% low-Pb 8,350
soil (< 50 ppm) collected in Leadville, Colorado
18 12 Galena-Enriched Soil NA A mixture of approximately 1.2% galenac and 98.8% low-Pb soil  11,200
(< 50 ppm) collected in Leadville, Colorado
19 12 California Gulch California Gulch NPL site, A composite of tailings samples collected from the Oregon 1,270
Oregon Gulch Tailings Leadville, Colorado Gulch tailings impoundment
Abbreviations: Fe, iron; Mn, manganese; NA, not applicable; NIST, National Institute of Standards and Technology; NPL, National Priorities List; PbO, Pb oxide; SRM, Standard Reference Material. 
aSamples were analyzed for Pb by inductively coupled plasma-atomic emission spectrometry in accordance with U.S. EPA Method 200.7 (U.S. EPA. 1994b); all samples were dried and
sieved to 250 µm before analysis, except for the two Aspen samples (study 5), which were sieved to 150 µm. bSRM 2589, composed of paint collected from the interior surfaces of houses
in the United States, contains a nominal Pb concentration of 10% (100,000 ppm); the material is powdered, with > 99% of the material < 100 µm in size. cGalena consisted of a mineralogic
(i.e., native) crystal of pure galena that was ground and sieved to obtain ﬁne particles < approximately 65 µm.[3]
where RLMi is the RLM for phase i, L is the
longest dimension of the particle, δ is the
density of the particle, and F is the fraction
(by mass) of Pb in the particle.
Dosing. A typical study consisted of
10 dose groups. Dose group 1 usually con-
sisted of three or five animals that were not
exposed to any exogenous Pb (control group);
all other dose groups consisted of ﬁve animals
per group. Dose groups 2, 3, and 4 were
exposed to Pb acetate, usually at doses of 25,
75, or 225 μg/kg/day. These dose levels were
based on results from Phase 0 and Phase I
investigations, which indicated that doses of
Pb acetate in the range of 25–225 μg/kg/day
Pb gave clear and measurable increases in Pb
levels in all end points measured (blood, liver,
kidney, bone). Animals in dose groups 5, 6,
and 7 were exposed to test material 1, and ani-
mals in dose groups 8, 9, and 10 were exposed
to test material 2. The doses of test materials
were usually set somewhat higher than for Pb
acetate (e.g., 75, 225, and 675 μg/kg/day Pb)
so that measurable responses would still be
likely even if the test material had a relatively
low RBA. Depending on the concentration of
Pb in the test material and the target dose level
for Pb, soil intake rates needed to achieve tar-
get Pb doses were usually in the range of
0.5–2.5 g/day.
Animals were exposed to Pb acetate or test
material for 15 days, with the dose for each
day being administered in two equal portions
given at 0900 hr and 1500 hr (2 hr before
feeding). We selected these exposure times so
that Pb ingestion would occur at a time when
the stomach was largely or entirely empty of
food, because the presence of food in the
stomach is known to reduce Pb absorption
(e.g., Blake et al. 1983; Chamberlain et al.
1978; Heard and Chamberlain 1982; James
et al. 1985; Rabinowitz et al. 1980). 
Dose material (Pb acetate or test material)
was placed in the center of a small portion
(~ 5 g) of moistened feed. This “doughball”
was administered to the animals by hand.
Dose calculations were based on measured
group mean body weights and were adjusted
every 3 days to account for animal growth. In
most cases, the animals readily ingested the
doughball, but occasionally an animal refused
or dropped the dose. In this event, the date
and amount of the missed dose were recorded
and the time-weighted average dose calcula-
tion for each animal was adjusted downward
accordingly.
Sample collection and analysis. Samples of
blood were collected from each animal 3 or
4 days before exposure began, on the ﬁrst day
of exposure (day 0), and on multiple days
thereafter (usually days 1, 2, 3, 5, 7, 9, 12,
and 15). All blood samples were collected by
venipuncture of the anterior vena cava, placed
immediately in purple-top Vacutainer tubes
(Becton, Dickinson and Company, Franklin
Lakes, NJ) containing calcium-EDTA (ethyl-
enediamine tetra-acetic acid) as anticoagulant,
and stored under refrigeration until analysis.
Blood samples were collected each sampling
day beginning at 0800 hr, approximately 1 hr
before the ﬁrst of the two daily exposures to
Pb on the sampling day and 17 hr after the
last Pb exposure the previous day. This blood
collection time was selected because the rate
of change in blood Pb resulting from the pre-
ceding exposures is expected to be relatively
small after this interval (LaVelle et al. 1991;
Weis et al. 1993).
One milliliter of whole blood from the
purple-top Vacutainer was added to 9.0 mL
of “matrix modifier” [0.2% (vol/vol) ultra-
pure nitric acid, 0.5% (vol/vol) Triton X-100,
and 0.2% (wt/vol; 0.015 M) dibasic ammo-
nium phosphate in deionized, double-distilled
water], a solution recommended by the
Centers for Disease Control and Prevention
(CDC) for analysis of blood samples for Pb
(CDC 2001). Samples of the matrix modiﬁer
were routinely analyzed for Pb to ensure the
absence of Pb contamination.
After collection of the ﬁnal blood sample
at 0800 hr on day 15, all animals were
humanely euthanized, and samples of liver
(medial lobe), kidney (both sides), and bone
(the right femur) were removed and stored
frozen in plastic bags for Pb analysis.
One gram of soft tissue (liver or kidney)
was placed in a screw-cap Teflon container
with 2 mL Optima-grade concentrated (70%)
nitric acid and heated in an oven to 90°C
overnight. After cooling, the digestate was
transferred to a clean 10 mL volumetric ﬂask
and diluted to volume with deionized, double-
distilled water.
The right femur of each animal was
deﬂeshed and dried at 100°C overnight. The
dried bones were then broken in half, placed in
a mufﬂe furnace, and dry ashed at 450°C for
48 hr. After dry ashing, the bone was ground
to a ﬁne powder using a mortar and pestle, and
200 mg was removed and dissolved in 10.0 mL
of 1:1 (vol:vol) Optima-grade concentrated
nitric acid/water. After the powdered bone was
dissolved and mixed, 1.0 mL of the acid solu-
tion was removed and diluted to 10.0 mL by
addition of 0.1% (wt/vol) lanthanum oxide in
deionized, double-distilled water.
Samples of biological tissue (blood, liver,
kidney, bone) and other materials (e.g., food,
water, reagents, solutions) were arranged in a
random sequence and provided to the U.S.
EPA analytical laboratory in a blind fashion
(identiﬁed to the laboratory only by a chain-
of-custody tag number). Each sample was
analyzed for Pb using a PerkinElmer model
5100 graphite furnace atomic absorption
spectrophotometer (PerkinElmer, Wellesley,
MA). Internal quality control samples were
run every 10th sample, and the instrument
was recalibrated every 15th sample. A blank,
duplicate, and spiked sample were run every
20th sample.
All results from the analytical laboratory
were reported in units of micrograms of Pb
per liter of prepared sample. The detection
limit was deﬁned as three times the SD of a set
of seven replicates of a low-Pb sample (typi-
cally ~2–5 μg/L). The SD was usually about
0.3 μg/L, so the detection limit was usually
about 0.9–1.0 μg/L. However, because differ-
ent dilution factors were used for different
sample types, the detection limit varied from
sample type to sample type. For prepared
blood samples (diluted 1/10), this corre-
sponded to a detection limit of 10 μg/L
(1 μg/dL). For soft tissues (liver and kidney,
also diluted 1/10), this corresponded to a
detection limit of 10 μg/kg wet weight. For
bone (ﬁnal dilution of 1/500), the correspond-
ing detection limit was 0.5 μg/g ashed weight.
Quality assurance. We took a number of
steps throughout each of the studies to assess
and document the quality of the data that were
collected. These steps are summarized below.
Duplicates. We submitted a randomly
selected set of about 5% of all blood and tissue
samples generated during each study to the
laboratory in a blind fashion for duplicate
analysis. There was good reproducibility
between duplicate samples for both blood and
tissues, with both linear regression lines having
a slope near 1.0, an intercept near zero, and an
R2 value near 1.00.
Performance standards for blood. We
obtained three sets of performance evaluation
blood samples from the CDC, with nominal
concentrations of 1.7 μg/dL, 4.8 μg/dL, and
14.9 μg/dL. Each day that blood samples were
collected from experimental animals, several
performance evaluation samples of different
concentrations were also prepared and submit-
ted for analysis in random order and in a blind
fashion. Analytical results obtained for the
performance evaluation samples were generally
in good agreement with the expected value at
all three concentrations, with an overall mean
of 1.4 μg/L for the low standards (nominal
concentration of 1.7 μg/L), 4.3 μg/L for the
middle standards (nominal concentration of
4.8 μg/L), and 14.5 μg/L for the high stan-
dards (nominal concentration of 14.9 μg/L).
Interlaboratory comparison. In each
study, we performed an interlaboratory com-
parison of blood Pb analytical results by send-
ing a set of about 15–20 randomly selected
whole-blood samples to the CDC for blind
independent preparation and analysis. The
results from the U.S. EPA laboratory were
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mean intersample difference (U.S. EPA value
minus CDC value) of 0.07 μg/dL. The slope
of the best-ﬁt straight line through the paired
data was 0.84, indicating that the concentra-
tion values estimated by the U.S. EPA labora-
tory tended to be about 15% lower than
those estimated by the CDC. The reason for
this apparent discrepancy between the U.S.
EPA laboratory and the CDC laboratory is
not clear but might be related to differences
in sample preparation techniques. Regardless
of the reason, the differences are sufficiently
small that they are likely to have no signifi-
cant effect on calculated RBA values. In par-
ticular, it is important to realize that if both
the Pb acetate and test material dose–response
curves are biased by the same factor, then the
biases cancel in the calculation of the ratio.
Approach for estimating RBA. The method
we used to estimate the RBA of Pb in a partic-
ular test material compared with the reference
material (Pb acetate) is based on the principle
that equal absorbed doses of Pb will produce
equal biological responses. By deﬁnition, 
Absorbed dosereference
= administered dosereference
× ABAreference [4]
and
Absorbed dosetest
= administered dosetest × ABAtest. [5]
When responses are equal, then absorbed
doses are equal, and 
Administered dosereference × ABAreference
= administered dosetest × ABAtest.
Thus,
[6]
That is, given the dose–response curve for some
particular end point (e.g., blood Pb AUC or the
concentration of Pb in liver, kidney, or bone)
for both the reference material and the test
material, the RBA may be calculated as the ratio
of administered doses that produce equal bio-
logical responses (and not as the ratio of
responses at equal doses). In this approach, the
mathematical form of the dose–response model
must be the same for both reference material
and test material. This is because the shape of
the dose–response curve is a function only of
the pharmacokinetic response of the biological
organism to an absorbed dose of Pb, and the
response per unit absorbed dose does not
depend on whether the absorbed Pb was
derived from reference material or test material.
Statistical methods for fitting dose–
response models. The techniques we used to
derive statistical models of the dose–response
data and to estimate the RBA are based on the
methods recommended by Finney (1978). All
model ﬁtting was performed using JMP (ver-
sion 3.2.2; SAS Institute Inc., Cary, NC).
As noted by Finney (1978), when the data
to be analyzed consist of two or more dose–
response curves from the same study (e.g., Pb
acetate, test material 1, test material 2), it is
apparent that all curves must have the same
intercept, because there is no difference
between the curves when the dose is zero. This
requirement is achieved by fitting all of the
data from a study simultaneously and requir-
ing the intercept to be identical for each curve.
Regression analysis based on ordinary least-
squares minimization assumes that the variance
of the responses is independent of the dose
and/or the response (Draper and Smith 1998).
In the present studies, this assumption is gener-
ally not satisﬁed because variability in response
tends to increase as a function of increasing
dose (heteroskedasticity). One method for deal-
ing with heteroskedasticity is through the use of
weighted least-squares regression (Draper and
Smith 1998). In this approach, each observa-
tion in a group of animals is assigned a weight
that is inversely proportional to the variance of
the response in that group:
[7]
where wi is the weight assigned to all data
points in dose group i and σi
2 is the variance
of responses in animals in dose group i. 
We considered several options for estimat-
ing the value of σi
2: 
• Option 1: using the observed variance (si
2)
in the responses of animals in dose group i
• Option 2: establishing a variance model of
the form σi
2 = αμi
ρ, where μi is the predicted
mean response for dose group i, and simulta-
neously ﬁtting the data to derive values of α
and ρ along with the other coefﬁcients of the
dose–response model using the data from a
particular study—an approach identical to
the nonconstant variance approach used by
U.S. EPA Benchmark Dose Software (U.S.
EPA 1995, 2001)
• Option 3a: establishing an “external” vari-
ance model based on an analysis of the
relationship between variance and mean
response using observations combined from
all studies and dose groups, and using that
model to predict the expected variance in
dose group i as a function of the predicted
mean response (i.e., the mean response pre-
dicted from the best-ﬁt equation through the
dose–response data) for that dose group
• Option 3b: establishing an “external” variance
model based on an analysis of the relationship
between variance and mean response using
observations combined from all studies and
dose groups, and using that model to predict
the expected variance in dose group i as a
function of the observed mean response level
(i.e., the mean response measured in the
exposed animals) for that dose group.
Based on a consideration of the advantages
and disadvantages of each approach, we
selected option 3b for use in this project;
option 3b is relatively less vulnerable than
other options to random variations in observed
variances in a dose group (which results in
assignment of weights that are either too high
or too low). We preferred this option over
option 3a because option 3a is based on pre-
dicted mean response, whereas option 3b is
based on observed mean response. It should be
noted, however, that option 3b is somewhat
vulnerable to poor fits when one particular
dose group in a data set lies well below the
expected smooth fit through the other dose
groups. In this case, the variance assigned to
the group (based on the observed mean
response) is lower than typical for that dose
level (and hence the weights assigned to the
data are higher than usual), tending to force
the line through that data set at the expense of
the other data sets.
The external variance model for option 3b
was based on the consolidated data from all
studies (Phase II). In this analysis, some dose
groups were excluded if the estimate of vari-
ance and/or mean response was judged to be
unreliable, based on the following two criteria:
a) the number of animals in the dose group
was < 3, or b) the fraction of responses below
the detection limit was > 20%. Figure 1 shows
the log-variance in response plotted as a func-
tion of the log-mean response in the group for
each of the end points. Log-variance increases
as an approximately linear function of log-
mean response for all four end points:
ln(si
2) = k1 + k2 × ln(y –
i), [8]
where y –
i is the mean observed response of ani-
mals in dose group i.
Values of k1 and k2 were derived from the
data for each end point using ordinary least-
squares minimization. The resulting values
are shown in Table 2. On the basis of these
variance models, we assigned the weights for
each response in a dose group based on the
observed mean response for that dose group:
σi
2 = exp[k1 + k2 × ln(y –
i)]. [9]
Choice of model forms. As noted above,
the main objective of the curve-ﬁtting effort is
to find a mathematical model that fits both
the reference and test group dose–response
data sets smoothly. There is no requirement
that the model have a mechanistic basis or that
wi
i
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,
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discussed by Finney (1978), it is generally not
appropriate to choose the form of the dose–
response model based on only one experiment;
the choice should be based on the weight of
observations across many different studies. We
evaluated four different models:
Linear:
y = a + bx [10]
RBA = btest/breference [11]
Exponential:
y = a + b × [1 – exp(–cx)] [12]
RBA = ctest/creference [13]
Michaelis-Menton:
y = a + bx/(c + x) [14]
RBA = creference/ctest [15]
Power:
y = a + bxc [16]
RBA = (btest/breference)1/c. [17]
For each data set, the preferred model was iden-
tiﬁed based on Akaike’s information criterion
(AIC) (U.S. EPA 2000a, 2001). On the basis of
ﬁtting each dose–response data set to each of
the four models above, we found that the linear
model most frequently gave the best ﬁt for liver,
kidney, and bone. In the few cases where the
linear model was not the best ﬁt, the RBA value
given by the linear model was usually close to
that given by whatever other model did provide
the best ﬁt. On this basis, we selected the linear
model for application to all dose–response data
sets for liver, kidney, and bone.
For the blood Pb AUC end point, the lin-
ear model usually gave the worst ﬁt; therefore,
we rejected it for the AUC end point. In gen-
eral, each of the three nonlinear models (expo-
nential, Michaelis-Menton, and power)
tended to give similar results in terms of RBA
value (the SD in RBA for a particular test
material averaged across the three models was
usually < 3%), and differences in the AIC
were usually small. On this basis, we con-
cluded that any of these three models would
be acceptable. The power model was not
selected because it does not tend toward a
plateau, whereas data from early blood Pb
pilot studies (using higher doses than com-
monly used in the Phase II studies) suggested
that the blood Pb end point does tend to do
so. Of the remaining two models (exponential
and Michaelis-Menton), the exponential
model was selected mainly because it yielded
the best ﬁt more often than did the Michaelis-
Menton model and because the exponential
model had been used in previous analyses of
the data. Thus, the exponential model was
selected for application to all dose–response
data sets for the blood AUC end point, except
in one special case, which is noted below.
In study 7 (test materials 11 and 12), the
blood Pb AUC data set did not yield a solution
in JMP for the exponential model, probably
because the data have relatively less curvature
than do most blood Pb AUC data sets. Because
of this lack of curvature, it was not possible to
estimate the exponential plateau value (b) with
conﬁdence, which in turn made it difﬁcult to
estimate the other parameters of the exponential
model. Several alternative approaches for data
reduction were evaluated, including using the
model fits from one of the other nonlinear
models, using the ﬁt for the linear model, and
ﬁtting the data to the exponential model using
a deﬁned value for the plateau based on results
from other data sets. The results (i.e., the RBA
values based on the blood Pb AUC end point)
were generally similar for all three of these
approaches, so the results from the linear fit
were used.
Assessment of outliers. For the purposes of
this program, end point responses that yielded
standardized weighted residuals > 3.5 or less
than –3.5 were considered to be potential out-
liers (Canavos 1984). A total of 13 such cases
occurred out of a total of 1,895 end point
responses (0.7%). In these cases, we calculated
RBA values both with and without the out-
liers. In most cases, there was very little differ-
ence (the average ratio of RBA with outlier
excluded to RBA with outlier included was
1.09). All results presented here are based on
the analysis with outliers excluded.
Uncertainty bounds in end-point–speciﬁc
RBA values. The uncertainty bounds around
each end-point–speciﬁc RBA value were esti-
mated based on Fieller’s theorem, as described
by Finney (1978).
Combination of RBA estimates across end
points. As discussed above, each study of RBA
used four different end points to estimate
absorption of Pb, including blood AUC, liver,
kidney, and bone. Consequently, each study
yielded four independent end-point–specific
estimates of RBA for each test material. Thus,
the final RBA estimate for a test material
involves combining the four end-point–speciﬁc
RBA values into a single value (point estimate)
and estimating the uncertainty around that
point estimate. The basic strategy selected for
deriving a point estimate of RBA for a test
material was to calculate a conﬁdence-weighted
average of the four end-point–specific RBA
values. Because each end-point–speciﬁc RBA
value is calculated as the ratio of the parameters
of the dose–response curves ﬁtted to the exper-
imental data for reference material and test
material, the relative confidence in an end-
point–speciﬁc RBA is inherently related to the
quality of the data that define the dose–
response curve for that end point. Thus, the
indicator we selected to quantify the relative
reliability of the four different end points is the
magnitude of the uncertainty (SE) around
RBA estimates based on each end point.
Casteel et al.
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Figure 1. External variance models for (A) blood AUC (y = 1.5516x – 1.3226; R2 = 0.5046; p < 0.01); (B) liver
(y = 2.0999x – 2.6015; R2 = 0.7966; p < 0.01); (C) kidney (y = 1.9557x – 1.8499; R2 = 0.7035; p < 0.01); and (D) femur
(y = 1.656x – 1.9713; R2 = 0.7022; p < 0.01).
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Table 2. Values for the variance model parameters
k1 and k2.
End point k1 k2
Blood AUC –1.3226 1.5516
Liver –2.6015 2.0999
Kidney –1.8499 1.9557
Femur –1.9713 1.656Figure 2 shows the SE in each RBA esti-
mate plotted as a function of the RBA value
for each of the four different end points.
Uncertainty in RBA (as reﬂected in the mag-
nitude of the SE) increases as a function of
the estimated value of RBA for all four end
points. This is expected because of the
heteroskedasticity in the underlying dose–
response data. Although RBA values based on
blood AUC or femur tend to yield estimates
with slightly lower SEs than RBA values based
on liver or kidney, the magnitude of the SEs
tends to be generally similar for all four end
points, and the difference between the four
regression lines is not statistically significant
(p = 0.699). Based on this, we judged each
end-point–speciﬁc RBA value to have approxi-
mately equal validity; thus, we calculated the
point estimate as the simple average across all
four end-point–speciﬁc RBA values.
The uncertainty bounds around each
point estimate were estimated using Monte
Carlo simulation. Each end-point–specific
RBA uncertainty distribution was assumed to
be normal, with the mean equal to the best
estimate of RBA and the SE estimated from
Fieller’s theorem. In the Monte Carlo simula-
tion, a value was drawn from one of the four
uncertainty distributions, with an equal prob-
ability of choosing each of the distributions.
The uncertainty in the point estimate was
characterized as the range from the 5th to the
95th percentile of these random values.
Results
Dosing effects on animal health and weight.
The Pb dose levels we used in this program
were substantially below levels that cause clini-
cal symptoms in swine, and we observed no
evidence of treatment-related toxicity in any
dose group. All animals exposed to Pb by the
oral route remained in good health through-
out each study; the only clinical signs observed
were characteristic of normal swine. Animals
typically gained about 0.3–0.5 kg/day, and the
rate of weight gain was normally comparable
in all exposure groups.
Time course of blood Pb response. Figure 3
presents an example graph of the time course
of pseudo-steady-state blood Pb levels after
repeated oral exposure to Pb acetate. Blood Pb
levels began below the quantitation limit (usu-
ally ~ 1 μg/dL) and stayed very low in control
animals throughout the course of the study. In
animals exposed to Pb acetate, blood Pb values
began to rise within 1–2 days and tended to
ﬂatten out to a near steady state within about
7–10 days. The temporal pattern was similar
for test materials that were absorbed well
enough to provide a clear response.
Dose–response patterns. Figures 4–7 pre-
sent the dose–response patterns observed for
blood, liver, kidney, and bone (femur) after
repeated oral exposure to Pb acetate. For
blood, the end point is the blood Pb versus
time AUC. For femur, kidney, and liver, the
end point is the concentration in the tissue at
the time of sacriﬁce. The data are based on the
combined results across all studies performed
during Phase II.
There was substantial variability in
response between individuals (both within and
between studies), and this variability tended to
increase as dose (and response) increased. As
noted above, this pattern of increasing variance
in response (heteroskedasticity) is accounted
for in the model-ﬁtting procedure through the
use of weighted least-squares regression.
Despite the variability in response, it is appar-
ent that the dose–response pattern was typi-
cally nonlinear for blood Pb AUC but was
approximately linear for liver, kidney, and
bone Pb. This pattern of dose–response
relationships suggests that, at least over the
dose range tested in this program, absorption
of Pb from the gastrointestinal tract of swine is
Relative bioavailability of lead
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Figure 2. Evaluation of relative precision of measurement end points. Fcrit, critical frequency. For blood
AUC, slope = 0.177, intercept = –0.002, and R2 = 0.867; for liver, slope = 0.227, intercept = 0.000, and R2 =
0.916; for kidney, slope = 0.219, intercept = 0.006, and R2 = 0.914; and for femur, slope = 0.162, intercept =
0.008, and R2 = 0.732. The results of the comparison of regression lines showed the following: F = 0.638;
Fcrit(0.05) = 2.227; and p = 0.699.
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Figure 3. Example time course of blood Pb response to Pb acetate and test material.
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+linear and that the nonlinearity observed in
blood Pb AUC response was due to saturable
binding in the blood compartment. This con-
clusion is based on the logic that, if the non-
linear behavior observed for blood were due to
nonlinear absorption from the gastrointestinal
tract, it would be extremely unlikely that all
three of the other end points observed (liver,
kidney, bone) would respond linearly.
Characterization of test materials. Table 3
lists the different Pb phases observed in the test
materials. Only a few of the phases are stoi-
chiometric minerals (anglesite = Pb sulfate,
cerussite = Pb carbonate, galena = Pb sulﬁde,
native Pb = Pb), whereas the others are non-
stoichiometric associations of various metals
and other elements. As shown in Table 3, of
the 22 different phases observed in one or
more samples, nine are very minor, with
RLM values no higher than 2% in any sam-
ple. However, 13 of the phases occur at con-
centrations that could contribute signiﬁcantly
to the overall bioavailability of the sample
(RLM > 10%). It should be noted that a Pb-
bearing particle that is present in a bulk sam-
ple from a slag pile is classiﬁed as slag only if
the particle is glassy or vitreous in nature.
Inclusions or other nonvitreous grains of
Pb-bearing material that may be present are
classified according to their mineral content
[e.g., Pb oxide (PbO), galena].
Table 4 summarizes information on the
degree to which Pb-bearing particles in each
sample are partially or entirely liberated (i.e.,
exposed to gastric fluids when ingested) or
included (i.e., fully enclosed or encased in
mineral or vitreous matrices). Data are pre-
sented both on a particle frequency basis and
on the basis of RLM. The majority of Pb-
bearing particles in most samples were partially
or entirely liberated, although test material 19
(Oregon Gulch tailings) is a clear exception.
Table 5 summarizes data on the frequency dis-
tribution of particle sizes (measured as the
longest dimension) in each sieved sample. For
convenience, the data presented are for liber-
ated particles only. Most samples contained a
range of particle sizes, often with the majority
of the particles being < 50 μm long.
RBA results for test materials. End-point–
speciﬁc RBA estimates for each test material are
summarized in Table 6. Inspection of the ﬁnal
point estimates for the different test materials
reveals a wide range of values across different
samples, both within and across sites. For exam-
ple, at the California Gulch site in Colorado,
RBA estimates for different types of material
range from about 6% (test material 19, Oregon
Gulch tailings) to about 105% [test material 12,
Fe/Mn (iron/manganese) PbO sample]. This
wide variability highlights the importance of
obtaining and applying reliable RBA data to
site-speciﬁc samples in order to help improve
risk assessments and more efﬁciently focus risk
management of childhood Pb exposure.
Reproducibility. Only one sample (test
material 14, Palmerton location 2) was ana-
lyzed in duplicate during the Phase II study.
As shown in Table 6, agreement is moderately
good between the two studies for the blood
AUC and kidney end points and for the point
estimate, although there is relatively low
agreement for the liver and bone end points.
Correlation of RBA with mineral phase. In
principle, each unique combination of phase,
size, and matrix association constitutes a
unique mineralogic form of Pb, and each
unique form could be associated with a unique
RBA that is the inherent value for that “type”
of Pb. If so, then the expected RBA value
observed for a sample containing a mixture of
different “types” of Pb is the concentration-
weighted average across all of the unique forms
present in the sample. If the number of differ-
ent Pb phases that may exist in the environ-
ment is on the order of ≥ 20, the number of
size categories is on the order of ﬁve, and the
Casteel et al.
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Figure 4. Dose–response curve for blood Pb AUC.
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Figure 5. Dose–response curve for liver Pb concentration.
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Figure 6. Dose–response curve for kidney Pb concentration.
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Figure 7. Dose–response curve for femur Pb concentration.
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(included, liberated), then the total number of
different “types” of Pb is on the order of
≥ 200. Because measured RBA data are avail-
able from this study for only 19 different sam-
ples, it is clearly impossible with the present
data set to estimate “type-speciﬁc” RBA values
for each combination of phase, size, and matrix
association. Therefore, to simplify the analysis
process, we assumed that the measured RBA
value for a sample was dominated by the liber-
ated mineral phases present, and we did not
consider the effects of included materials and
particle size. That is, the data were analyzed
according to the following model:
[18]
where RBAsample is the observed RBA of Pb in
a sample, Ci, liberated is the fraction of total Pb
in liberated particles of phase i, RBAi, liberated is
the RBA of Pb in liberated particles of phase
i, and n is the number of different Pb phase
categories. 
Because 22 different phases were identiﬁed
and only 19 different samples were analyzed, it
was necessary to reduce the number of phases
to a smaller number so that regression analysis
could be performed. Therefore, the different
phases were grouped into 10 categories, as
shown in Table 7. These groups were based on
professional judgment regarding the expected
degree of similarity among the different phases,
along with information on the relative abun-
dance of each phase (Table 3). The total Pb
mass in each phase grouping was calculated by
summing the RLM for each individual compo-
nent in the group. As noted above, only the Pb
mass in partially or entirely liberated particles
was included in the sum. Group-speciﬁc RBA
values were estimated by fitting the grouped
data to the model using minimization of
squared errors. Each parameter was constrained
to be ≥ 0. Because group 10 contains only
phases that are present in relatively low levels,
an arbitrary coefﬁcient of 0.5 was assumed for
this group, and the coefﬁcient was not treated
as a ﬁtting parameter.
The resulting estimates of the group-
specific RBA values are shown in Figure 8.
There is a wide range of group-specific RBA
values. It is important to stress that these group-
speciﬁc RBA estimates are derived from a very
limited data set (nine independent parameter
RBA = ( RBA sample ,liberated ,liberated Cii
i
×
= =
∑
1
n
),
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Table 3. RLM (%) of mineral phases observed in test materials.
Test material
Phase 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19
Anglesite —  28 1 0.5 1.0 2 7 1 —  36 10 — 2 6 4 — 1 —  — 
As(M)  oxide — — — — — — — — — — — — — — —  0.003 — — — 
Calcite — — 0.2 — — 0.1 — — — — — — — — — — — — — 
Cerussite 2 0.3 32 81 1.1 57 62 64 4 0.3 20 — 1 —  —  14 55 —  — 
Clay — —  0.018 0.003 —  0.017 0.1 — — 0.1 —  0.01 —  0.03 0.13 — — — — 
Fe/Pb oxide 6 3 14 2 2 10 9 7 0.3 7 6 8 51 2 2 0.13 —  —  — 
Fe/Pb sulfate 22 30 3 1 0.3 1 5 5 0.1 20 6 3 0.3 1 —  0.6 —  —  — 
Galena — 9 — 8 9 3 12 17 6 12 2 — 3 —  —  20 —  100 100
Pb  barite —  0.04 — — —  0.01 0.06 — —  0.007 0.15 0.14 —  1 0.1 — — — — 
Organic  Pb — 0.3 — — — —  0.03 0.03 — —  0.11 0.11 1 — — — — — — 
PbO — —  0.09 — 69 7 — — — — — — — — — 27 44 — — 
Pb  phosphate 50 26 21 6 —  7 1 1 — 3.6 30 15 — 24 1 — — — — 
Pb  silicate — — —  0.04 — 0.5 — — — — 1.9 0.8 — — 1.4 — — — — 
Pb  vanadate — — — — — — — — — — 0.1 0.4 — — 18 — — — — 
Mn/Pb  oxide 18 2 2 2 0.8 9 4 5 —  20.2 22 72 — 66 66 — — — — 
Native  Pb — — 22 — 0.7 2 — — 15 — — — — — — — — — — 
Pb(M)  oxide — — — —  4 — — — 26 — — — — —  7 3 — — — 
Pb/As  oxide 2 1 —  0.15 6 — — — 33 — 0.1 — 31 — — 29 — — — 
PbO/cerussite — — — — — — — — — —  1 — — — — — — — — 
Slag — — 4 —  7 1 — — 16 —  1 — 10 — —  6 — — — 
Sulfosalts — — — — — — — — 0.4 — — — — — — — — — — 
Zn/Pb  silicate — — — —  0.03 — — — — — — — — —  2 — — — — 
Abbreviations: —, not observed; As, arsenic; M, metal; Zn, zinc.
Table 4. Matrix associations of Pb particles in test
materials.
Test Particle frequency (%) RLM (%)
material Liberated Included Liberated Included
1 100 0 100 0
2 100 0 100 0
3 8 11 9 7 62 4
4 100 0 94 6
5 8 71 3 7 72 3
69 6 4 9 3 7
78 6 1 4 9 3 8
89 8 2 9 4 6
9 91 9 77 23
10 91 9 91 9
11 79 21 65 35
12 98 2 100 0
13 78 22 80 20
14 100 0 100 0
15 79 21 89 11
16 80 20 70 30
17 100 0 100 0
18 100 0 100 0
19 2 98 5 95
Table 5. Length distributions (%) for Pb-bearing particles in test materials.
Test Particle size (µm)
material < 5 5–9 10–19 20–49 50–99 100–149 150–199 200–249 > 250
1 3 8 2 2 1 9 1 642000
2 66 13.6 10 6.1 3 1 0 0 0
3 4 4 1 9 8 899211
4 2 9 2 0 2 1 2 083000
5 14 13 15 6 20 24 4 3 0
6 2 3 2 1 2 2 1 996110
7 2 7 1 9 2 2 1 786110
8 3 8 3 5 1 2 842000
9 6 1 342 02 91 81 3 5
10 23 15 14 23 14 9 2 1 0
11 24 9 18 22 15 9 1 1 1
12 26 19 24 17 10 4 0 0 0
13 19 8 8 5 9 19 10 13 9
14 26 23 25 18 6 1 0 0 0
15 25 15 21 25 13 2 0 0 0
16 23 10 29 17 6 8 3 3 1
17 76 4 6 8 6 0 0 0 0
18 48 2 4 41 4 0 0 0 0
19 85 8 6 0 0 0 0 0 0estimates based on only 19 different measure-
ments), so the group-specific RBA estimates
are inherently uncertain. In addition, both the
measured sample RBA values and the RLM in
each phase are subject to additional uncer-
tainty. Therefore, the group-speciﬁc RBA esti-
mates should not be considered highly precise
and calculation of a quantitative sample-spe-
cific RBA value from these estimates is not
appropriate. Rather, it is more appropriate to
consider the results of this analysis as sufﬁcient
to support only semiquantitative (low,
medium, high) classiﬁcation of phase-speciﬁc
RBA values. As noted above, the estimates
apply only to particles that are liberated, not to
those that are included.
Conclusions
Juvenile swine are believed to be a useful
model of gastrointestinal absorption in chil-
dren. The results from the studies conducted
during this program indicate that juvenile
swine can be used to measure Pb RBA in a
variety of soil-like test materials. Each RBA
estimate is uncertain because of the variability
in response between different animals, but the
magnitude of this uncertainty can be quanti-
ﬁed to allow risk managers ﬂexibility in choos-
ing a value for use in risk assessment and risk
management decision making. If necessary,
the magnitude of the uncertainty can be
reduced by using more animals per dose group
and/or more dose groups to help define the
dose–response curves with greater certainty.
Each of the four different end points
employed in these studies (blood AUC, liver,
kidney, bone) to estimate RBA appear to
yield reasonable values, with no one end
point being clearly superior to the others.
Thus, the best estimate of the RBA value for
any particular sample is the average across all
four end-point–specific RBA values, and
combining results from the independent end
points helps increase conﬁdence in the point
estimate.
There are clear differences in the RBA of
Pb between different types of test material,
ranging from near zero to close to 100%.
Thus, reliable data on the RBA value for dif-
ferent types of test materials at a site can be
very important in improving Pb risk assess-
ments at a site. The U.S. EPA default value
for the RBA of Pb in soil is 60% (U.S. EPA
1994a). Of the 17 authentic site soil samples
tested in this program, 8 had point estimate
values within 20% of the default (i.e., from
40 to 80%), 6 had point estimate RBA values
< 40%, and 3 had point estimate values
> 80%. Thus, based on this set of samples,
the U.S. EPA default value of 60% appears to
be a reasonable central tendency value.
Presumably, the RBA value for any one
sample is a weighted function of the “phase-
speciﬁc” RBA values for each Pb phase present
in the sample. Available data support the view
that certain types of Pb minerals are well
absorbed (e.g., cerussite, Mn/Pb oxide),
whereas other forms are poorly absorbed (e.g.,
galena, anglesite). However, the data are not
yet sufﬁcient to allow reliable quantitative cal-
culation or prediction of the RBA for a test
material based on knowledge of the Pb mineral
content alone.
Casteel et al.
1170 VOLUME 114 | NUMBER 8 | August 2006 • Environmental Health Perspectives
Table 6. Estimated Pb RBA values for test materials.
Test Blood AUC Liver Kidney Femur Point estimate
material RBA LB UB RBA LB UB RBA LB UB RBA LB UB RBA LB UB
1 0.34 0.23 0.50 0.28 0.20 0.39 0.22 0.15 0.31 0.24 0.19 0.29 0.27 0.17 0.40
2 0.30 0.20 0.45 0.24 0.17 0.34 0.27 0.19 0.37 0.26 0.21 0.31 0.27 0.19 0.36
3 0.65 0.47 0.89 0.56 0.42 0.75 0.58 0.43 0.79 0.65 0.52 0.82 0.61 0.43 0.79
4 0.94 0.66 1.30 1.00 0.75 1.34 0.91 0.68 1.24 0.75 0.60 0.95 0.90 0.63 1.20
5 0.47 0.33 0.67 0.51 0.33 0.88 0.31 0.22 0.46 0.31 0.23 0.41 0.40 0.23 0.64
6 0.84 0.58 1.21 0.86 0.54 1.47 0.70 0.50 1.02 0.89 0.69 1.18 0.82 0.51 1.14
7 0.69 0.54 0.87 0.87 0.58 1.39 0.73 0.46 1.26 0.67 0.51 0.89 0.74 0.48 1.08
8 0.72 0.56 0.91 0.77 0.50 1.21 0.78 0.49 1.33 0.73 0.56 0.97 0.75 0.50 1.04
9 0.21 0.15 0.31 0.13 0.09 0.17 0.12 0.08 0.18 0.11 0.06 0.18 0.14 0.07 0.24
10 0.19 0.14 0.29 0.13 0.09 0.19 0.15 0.09 0.22 0.10 0.04 0.19 0.14 0.06 0.23
11 0.88 0.62 1.34 0.75 0.53 1.12 0.73 0.50 1.12 0.53 0.33 0.93 0.72 0.38 1.07
12 1.16 0.83 1.76 0.99 0.69 1.46 1.25 0.88 1.91 0.80 0.51 1.40 1.05 0.57 1.56
13 0.26 0.19 0.36 0.19 0.11 0.32 0.14 0.08 0.25 0.20 0.13 0.30 0.20 0.09 0.31
14 0.82 0.61 1.05 0.60 0.41 0.91 0.51 0.30 0.91 0.47 0.37 0.60 0.60 0.34 0.93
15 0.62 0.47 0.80 0.53 0.37 0.79 0.41 0.25 0.72 0.40 0.32 0.52 0.49 0.29 0.72
16 0.70 0.54 0.89 0.58 0.42 0.80 0.36 0.25 0.52 0.39 0.31 0.49 0.51 0.29 0.79
17 0.86 0.66 1.09 0.73 0.52 1.03 0.55 0.38 0.78 0.74 0.59 0.93 0.72 0.44 0.98
18 0.01 0.00 0.02 0.02 0.00 0.04 0.01 0.00 0.02 0.01 –0.01 0.03 0.01 0.00 0.03
19 0.07 0.04 0.13 0.11 0.04 0.21 0.05 0.02 0.09 0.01 –0.04 0.06 0.06 –0.01 0.15
14Ra 0.71 0.55 0.99 1.25 0.82 2.03 0.54 0.35 0.80 0.95 0.69 1.30 0.86 0.43 1.52
Abbreviations: LB, 5% lower conﬁdence bound; UB, 95% upper conﬁdence bound. 
aRepeat analysis of test material 14.
Table 7. Grouped Pb phases.
Group Group name Phase constituents
1 Galena Galena (PbS)
2 Cerussite Cerussite
3 Mn(M) oxide Mn/Pb oxide
4 PbO PbO
5 Fe(M) oxide Fe/Pb oxide (including
Fe/Pb silicate)
Zn/Pb silicate
6 Pb phosphate Pb phosphate
7 Anglesite Anglesite
8 Pb(M) oxide As(M) oxide
Pb silicate
Pb vanadate
Pb(M) oxide 
Pb/As oxide
9 Fe(M) sulfate Fe/Pb sulfate
Sulfosalts
10 Minor constituents Calcite
Clay
Pb barite
Organic Pb 
Native Pb
PbO/cerussite
Slag
M, metal.
Figure 8. Estimated group-specific RBA values,
with groups as deﬁned in Table 7.
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